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There are increasing global concerns about the role of foods in health and chronic 
diseases. Milk and dairy products are important sources of dietary protein and fat 
in the diets of many cultures including African communities. However, questions 
are being raised concerning the role of milk-nutrients in chronic diseases including 
CVDs. Also, the African public often does not have access to scientific 
information on the nutritional and health significance of nutrients in some of their 
major foods including milk and dairy products. This review of the literature was 
therefore conducted in order to provide information on the role of the fatty acids of 
milk and dairy products in respect of CVDs, with reference to some African 
communities. The fatty acids linoleic and alpha-linolenic are precursors of 
eicosanoids, whose excessive and/or imbalanced synthesis has been implicated in 
various pathological conditions including CVD. Due to the considerable amount of 
saturated fatty acids and cholesterol in milk, its consumption is often associated 
with mortalities from CVDs. Myristic and lauric acids are atherogenic, and raise 
the risk of CVD by increasing plasma cholesterol and LDL, although oleic, linoleic 
and linolenic reduce the increase. Palmitic acid does not seem to be strongly 
atherogenic, while stearic acid is largely neutral. Abundant intake of saturated fats 
increases plasma LDL and VLDL. Although considered high cholesterol foods, 
milk and dairy products may not be major contributors of dietary cholesterol, as 
whole milk contains 10-15 mg cholesterol/dL, while skimmed milk with 1% 
butter-fat contains less than 8 mg/dL cholesterol. Trans fats have been implicated 
as risk factors for CVD due to their hypercholesterolemic effect. The risks of CVD 
from trans fats intake in milk and its products are, however, lower compared to 
risks from the consumption of hydrogenated vegetable oils. Linoleic, α-linolenic 
and oleic acids are considered cardioprotective. The short and medium-chain fatty 
acids do not seem to influence plasma cholesterol levels; monounsaturated fats 
tend to have a neutral influence, while polyunsaturated fats tend to lower total 
cholesterol, but may also lower the “good” HDL. To lower cholesterol and 
saturated fatty acids intake from milk and dairy products, and to slow 
atherosclerosis progression, it is recommended that the consumption of full-fat 
milk be reduced while increasing that of skimmed milk and cheese. This can be 
achieved by integrating these findings into food processing practices, agricultural, 
and nutritional policy in Africa.   
  






LE ROLE D'ACIDES GRAS 
Lokuruka, Ph.D. 
 
Les acides myristiques et lauriques sont athérogènes, et ils aggravent le risque de 
maladies cardiovasculaires en augmentant le cholestérol du plasma et la LDL bien que 
l’oléique, le linoléique et le linolénique  réduisent l'accroissement. L’acide palmitique ne 
semble pas être pas fortement athérogénique, tandis que l’acide  stéarique est largement 
neutre. La prise abondante de matières grasses saturées augmente la LDL et la VLDL du 
plasma. Tout en étant considérés comme des aliments contenant beaucoup de 
cholestérol, le lait et les produits laitiers ne peuvent pas être des contributeurs majeurs du 
cholestérol diététique, étant donné que le lait entier contient 10 -15 mg de cholestérol/dL, 
tandis que le lait écrémé à 1% de beurre – matière grasse contient moins de 8 mg/dL de 
cholestérol. Les acides gras trans ont été considérés comme des facteurs de risques de 
maladies cardiovasculaires à cause de leur effet hypercholestérolémique. Les risques de 
maladies cardiovasculaires provenant de  la prise de matières grasses trans dans le lait et 
les produits laitiers sont, cependant, peu élevés en comparaison avec les risques de la 
consommation d’huiles végétales hydrogénées. Les acides linoléiques, a-linoléniques et 
oléiques sont considérés comme cardioprotecteurs. Les acides gras courts et moyens ne 
semblent pas influencer les niveaux du cholestérol du plasma; les matières grasses 
mono-insaturées tendent à avoir une influence neutre, tandis que les matières grasses 
poly-insaturées tendent à baisser le cholestérol total, mais ils peuvent également baisser 
la "bonne" HDL (lipoprotéine de haute densité). Pour diminuer le cholestérol et la prise 
d’acides gras saturés du lait et des produits laitiers et  ralentir la progression de 
l’athérosclérose, il est recommandé que de réduire la consommation de lait entier en 
augmentant la consommation de fromage et lait écrémés. Ceci  peut se réaliser en 
intégrant les présents résultats dans les pratiques de transformation des produits 
alimentaires,  ainsi que dans la politique agricole et alimentaire en Afrique.     
   











Cows, sheep, goats and camels are the milk-animals in Africa. The camel is 
important in North Africa, the Horn of Africa, Somalia, northern and northeastern 
Kenya.  
 
Milk is a source of protein, lactose and fats in the diets of many African 
communities. Dietary fats supply energy, carry the fat-soluble vitamins, and are a 
source of antioxidants and bioactive compounds [1]. Fatty acids (FAs) mainly 
comprise saturated (SAFAs), monounsaturated (MUFAs) and polyunsaturated fatty 
acids (PUFAs). The latter are classified into essential and nonessential fatty acids. 
The essential fatty acids linoleic (9, 12-octadecadienoic acid-18:2n-6) and alpha-
linolenic (9, 12, 15-octadecatrienoic acid-18:3n-3) are precursors of eicosanoids [2, 
3]. Excessive and/or imbalanced synthesis of eicosanoids has been implicated in 
various pathological conditions, including thrombosis, inflammation, asthma, 
ulcers and kidney disease [4]. An inadequate dietary intake of essential fatty acids 
(EFAs) precipitates essential fatty acid deficiency disease. Five to 10% of an 
adult’s calories need to come from fat to maintain health, and 2-3% of these 
calories have to be supplied by the EFAs or 1-2% energy as linoleic acid (LA) [5, 
6]. FAs are needed for infant nutrition, growth and development. Maternal milk, 
from mothers of preterm infants, contains higher concentrations of long-chain 
polyunsaturated fatty acids (LC-PUFAs)-in particular, docosohexaenoic acid 
(DHA, 22:6n-3), than either cow’s milk or most infant formulae [7], implying the 
essentiality of DHA for preterm infants. Phospholipids are incorporated as 
structural components of the brain and all cell membranes [5]. The PUFAs from 
animal feed are hydrogenated as they pass through the cow's four stomachs by 
resident intestinal microflora. PUFAs and MUFAs are prone to autooxidation 
under adverse processing and storage conditions. Lipid peroxidation products have 
been shown to cause endothelial damage both in vivo and in vitro [8]. They may 
therefore promote atherogenecity. Cholesterol performs many important roles in 
the body despite the bad publicity associated with it [9]. It is the backbone of 
steroid hormone synthesis, synthesis of bile acids, and is essential for stabilizing 
cell membrane constituents, plasma lipoproteins and myelin. The American Heart 
Association (AHA) recommends limiting dietary cholesterol to less than 300 
mg/day due to its role in atherosclerosis [10].  
 
GENERAL RISK FACTORS FOR CARDIOVASCULAR DISEASES (CVDs) 
 
CVD refers to any disease that affects the cardiovascular system although it 
usually refers to atherosclerosis, systemic hypertension, syphilitic heart disease, 
and rheumatic heart disease. Coronary atherosclerosis develops with the formation 
of fatty fibrous plaques that narrow the lumen of the coronary and peripheral 
arteries and may lead to thrombosis or myocardial infarction. CVD is multi-
faceted, and the course of its pathology is influenced by physiology, genetics, the 





CVD include increasing age, the male sex (gender), heredity (including race), 
while the major identified modifiable risk factors include cigarette smoking, 
elevated blood pressure, elevated plasma cholesterol, obesity, diabetes mellitus and 
elevated plasma triglycerides [12, 13]. Diet is an important part of the control and 
management of CVD; diet involves a modifiable set of factors, which if well 
managed can reduce the risk of CVD as most variables including diabetes mellitus, 
obesity, low-density lipoprotein (LDL) levels, triacylglycerol levels, alcohol and 
blood pressure are all connected to diet.  
 
CVD is currently the commonest global cause of death for mankind, with an 
estimated 17 million deaths/year, which are projected to reach 25 million by 2020 
[14].  It is the number one cause of death in the U.S., U.K., Australia and Europe 
(except in France) [12, 15, 16, 17]. It is responsible for 33, 40, 39, 40 and 39% of all 
deaths in the World, U.S., U.K., Australia and Europe, respectively. The 2004 World 
Health Report estimates that CVD is the largest cause of death in the lowest 
socioeconomic groups in developed countries and 85% of all deaths in low-income 
and middle-income countries are due to it [14]. However, deaths from HIV/AIDS 
related illnesses are currently greater in some sub-Saharan African countries than 
those due to malaria, tuberculosis and/or CVD. In Kenya, HIV/AIDS claims 100 000-
150 000 lives annually compared to over 42 000, 30 000 and 20 000 by CVD, malaria 
and tuberculosis, respectively [14]. In 2002, cerebrovascular disease, ischaemic 
stroke and other CVDs represented 31.9, 37.1 and 31.1% of 20 000 deaths attributed 
to CVDs in males, and 37.0, 27.5 and 35.6% of 24 000 female deaths in Kenya [14]. 
Ischaemic stroke and cerebrovascular disease were the main CVD sub-type killers of 
Kenyan males and females, respectively.   
 
In developing countries, there are indications that deaths from CVD are rising with 
changes in lifestyles, “modernization,” urbanization and occupational sedentarization 
[14].   
 
Hyperlipidemia, which is associated with elevated levels of cholesterol, cholesteryl 
esters and triglycerides, has been identified as a major risk factor for atherosclerosis 
[18]. These lipid components are transported in the circulatory system in association 
with proteins, carbohydrates and phospholipids in various micelle forms, e.g., 
chylomicrons (CMs), very low density lipoproteins (VLDLs), intermediate-density 
lipoproteins (IDLs), low-density lipoproteins (LDLs), high-density lipoproteins 
(HDLs), lipoprotein A (LpA) and various micelle remnants [13]. HDL (the “good” 
cholesterol) carries cholesterol back to the liver from the bloodstream and is 
thought to be protective by taking the extra cholesterol out of the blood. LDLs (the 
“bad” cholesterol) transport cholesterol through the blood to the cells and usually 
comprise most of the blood cholesterol. VLDLs also keep cholesterol in circulation 
and may contribute to atherosclerosis [18]. The LDL, total cholesterol/HDL and/or 
the LDL/HDL ratios are often assumed to be relative measures of CVD risk. A 
ratio of LDL/HDL above 5.0, total cholesterol, LDL, and triglyceride levels above 
200, 150, and 150 mg/dL, respectively, and HDL below 35 mg/dL are believed to 






It is well established that individuals with premature CVD exhibit some or all of the 
following: a) increased LDL levels; b) increased cholesteryl esters and triglycerides, 
primarily as VLDLs; and c) increased triglycerides with normal cholesterol, primarily 
as VLDLs [13]. Several prospective studies have found a positive correlation between 
serum LDL and atherosclerotic events, and this appears to be inversely related to 
serum HDL [20]. However, the cardioprotective effect of HDL does not contribute to 
explain CVD mortality differences between populations. Also, despite the widespread 
acceptance of the role of LDL-cholesterol, it remains true that many patients suffering 
from myocardial infarction have relatively normal levels of LDL-cholesterol [18]. 
This underlines some lack of clarity and knowledge on the specific roles and 
interaction of CVD risk factors. Also, there is still ongoing debate as to whether high 
LDL-cholesterol or low HDL-cholesterol is the better predictor of CVD risk.  
 
CVD RISK FACTORS ASSOCIATED WITH MILK AND DAIRY PRODUCTS 
 
Milk is considered a risk factor for atherosclerosis and coronary heart disease (CHD) 
because of its cholesterol content, SAFAs and possibly lactose [21]. However, while 
epidemiological data to support these assertions are scanty and inconclusive, there is 
almost complete lack of clinical data. Triacylglycerols compose 97-98% of milk 
lipids with the rest being sterols (mainly cholesterol, 1.1%) and phospholipids 
(0.45%) [22]. Bovine milk therefore contains 15 and 7-8 mg/dL cholesterol and 
phospholipids, respectively. Ross proposed the “response to injury hypothesis” as the 
primary cause of atherosclerosis [23]. Injury to endothelial cells can arise from 
exposure to endotoxins, vasoactive amines, viral infections, lipid oxides, 
hypercholesterolemia, mechanical injury (hypertension), carbon monoxide, and/or 
hyperlipidemia [13]. Serum cholesterol levels in a given population are closely 
related with increased risk for atherogenesis [18, 24]. However, skepticism still 
remains regarding the relationship between dietary cholesterol intake and serum 
cholesterol concentrations [25, 26].  
 
The seven-country study [27] gave rise to the idea that saturated fats contribute to 
high plasma cholesterol and atherogenesis, but skepticism still remains about the 
degree of such an effect [28]. Merskey and Marcus in a review concluded that there 
was no evidence that the type of saturated dietary fat had any influence on 
coagulation [29].  Among 350 rural Maasai men of Kenya over the age of 40 who 
were examined for CVD, only one had an equivocal ECG-based evidence of a 
myocardial infarction [28]. Dietary evaluations showed a daily intake of 300 g animal 
fat, with 25% young men showing plasma cholesterol of 600 mg/dL, all from 
fermented milk and meat. The serum cholesterol level among the warrior age-group 
of the Maasai averaged 150 mg/dL, and did not significantly rise with age. In another 
group of 400 rural Maasai men and women, the mean plasma cholesterol was 120 
mg/100 mL despite the consumption of large amounts of full-fat milk and meat 
containing considerable amounts of saturated fats [28].  
 
According to Shaper, the Samburu, another group of nomadic livestock herders in 
northern Kenya consumed about 200-400 g fat/day, mainly saturated fat from milk 





Maasai [30].  All Samburu age-groups consumed more milk than the Maasai but their 
blood lipid profiles resembled those of populations living on low-fat diets. In 
autopsies of the hearts and aortae of 50 Maasai men, who died suddenly from natural 
causes, examination of the aortae showed extensive atherosclerosis with lipid 
infiltration and fibrous changes but with very few complicated lesions [28]. It was 
evident that although their arteries showed intimal thickening by atherosclerosis 
which equalled that of old U.S. men, the Maasai blood vessels enlarged with age to 
more than compensate for this disease. It was postulated that they are protected 
partially from atherosclerosis by physical fitness (from the extensive walking in the 
course of herding), which causes their coronary vessels to be capacious [28]. A recent 
large prospective study involving 47 721 Finnish subjects 25-64 years of age, without 
a history of coronary heart disease, stroke, or cancer at baseline, supported Mann’s 
assertions; the study spanning over 19 years established an inverse correlation 
between the level of physical activity and ischaemic heart disease [31]. It is 
established that a high level of leisure time physical activity including active 
commuting reduces the risk of all subtypes of stroke. The absence of salt in their low 
carbohydrate, high-protein dairy and meat diets, the beneficial effect of the probiotic 
natural cultures that ferment their milks, and low levels of stress may also have 
contributed to the low incidence of CVDs in the above livestock-herding populations. 
 
Three recent case-control studies concluded that a high-carbohydrate, low-fat diet 
offers no more protection against atherosclerosis than does a low-carbohydrate, 
high-fat diet [32]. While these studies did not seem to have controlled all 
confounding variables, they disprove the conventional wisdom that animal fat is 
the primary dietary cause of coronary diseases. Nevertheless, it is increasingly 
being demonstrated on the basis of convincing evidence that saturated fats and 
high serum cholesterol levels may indeed contribute to the build up of atherogenic 
plaques in arterial walls thereby possibly leading to CVDs. A review of clinical 
trials and dietary interventions revealed that it is possible to reduce the incidence of 
coronary death and nonfatal myocardial infarction, as well as manifestations of 
atherosclerosis in cerebral and peripheral arteries, by reducing the dietary intake of 
saturated fat and cholesterol [33]. Also, cholesterol oxidation products, cholestane-
3ß, 5α, 6ß-triol and  
 
25-hydroxycholesterol, produce endothelial damage both in vivo and in vitro [8]. 
This is likely to lead to CVD.  
 
Although there is general agreement that reducing dietary cholesterol, saturated fats 
and possibly trans fatty acids would be beneficial, controversy still remains as to 
what constitutes beneficial dietary fats. The long-chain ω-3 PUFAs, eicosapentaenoic 
acid (EPA) and DHA, commonly found in seafood, are the only FAs that have 
consistently been shown to significantly reduce the risk of CVD in human kinetic 
studies [6]. Some dairy fatty acids are also cardioprotective.  
 
Milk is not a high-fat food and yet due to its considerable cholesterol and SAFA 
content, its considerable consumption is suspected to lead to higher risk for CVD. 





(12.1%), myristic (10.1%), butyric (3.2%), lauric (2.8%), decanoic (2.4%) and 
linoleic (2.3%) [34]. Camel milk contained palmitic (31.5%), oleic (25.0%), stearic 
(14.0%), palmitoleic (10.4%) and myristic (10.1%) [35], while goat milk contained 
oleic (28.1%), palmitic (21.3%), stearic (14.4%), myristic (7.7%) and capric (5.4%) 
[36]. Due to the higher content of stearic and oleic acid as well as MUFA in camel 
milk, it may be more favourable for human nutrition than cow’s and/or goat milk. 
Myristic, lauric and palmitic are atherogenic and raise the risk of CHD by increasing 
plasma cholesterol and LDLs [22]. However, 18:0, 18:1 and 18:2 reduce the increase 
[37]. Palmitic does not seem to be strongly atherogenic and has not been shown by 
some workers to raise LDL-cholesterol [38, 39]. However, Grundy showed it 
potentially raises plasma cholesterol [40]. Although considered high cholesterol 
foods, milk and dairy products are minor contributors to dietary cholesterol as whole 
milk contains 10-15 mg cholesterol/dL [9, 22], while 1% fat skimmed milk contains 
less than 8 mg/dL cholesterol [9].  The cholesterol intake from bovine milk in Kenya 
as calculated by this author based on a fat content of 3.3% is 71 and 89 
mg/day/person from the production of 2.8 and 3.5 billion litres full-fat milk in 2000 
and 2004, respectively. However, the 2000 milk production excluded milk from 
camels, while the 2004 milk production excluded that from sheep, goats and camels 
[41, 42]. Cholesterol intake from milk and dairy products in Kenya is therefore likely 
to be higher than 89 mg/person/day and the consequences for the health of the 
consumers are currently undetermined. The cholesterol intake by Kenyans from 
meats is also unaccounted for.  The current per capita consumption of milk in Kenya 
is 113 litres or 310 mL/day [42], which is similar to the American per capita 
consumption [43]. Milk and cheese consumption and consequently of calcium did not 
seem to increase the risk of non-fatal acute myocardial infarction (AMI) in an Italian 
population characterized by comparably low milk consumption of 137 mL/day 
among cases and 148 mL/week among controls, but a high intake of cheese (average 
intake of 36.4 g/day among cases and 40.0 g/day among controls [21]. However, in a 
small controlled trial over a 6-week period, consumption of 236 mL/day skim and 
whole milk by 8 healthy males showed that substitution of skim milk for whole milk 
decreases the risk of CHD [44]. The daily cholesterol and SAFAs intake has recently 
been estimated in British adults as 223 mg and 42 g in males, and 223 mg and 31 g in 
females, respectively [45]. This compares with the American daily intake of 337 mg 
cholesterol and 35 g saturated fat by males and 217 mg cholesterol and 22 g saturated 
fat by females [46]. Unlike the rural Maasai and Samburu of Kenya, plasma 
cholesterol rises with age in both American and British adults [45, 46]. Furthermore, 
despite the reduction in the intake of meats and milk, and therefore of cholesterol and 
saturated fats in the U.S. and British diets between 1965 and 1995, CVD mortality 
still remains high [45, 46). 
 
Butter with 80% fat contains 190-200 mg cholesterol/100 g [9, 22]. However, 
because butter is consumed in small quantities it should not be a major nutritional 
concern; nevertheless, the large amounts of atherogenic fatty acids could along with 
those from other dietary sources hasten atherogenesis in susceptible individuals [22].  
The presence of trans fatty acids in foods has recently elicited scrutiny from the 
scientific community. Most unsaturated fatty acids in nature are found in the cis 





processing in oil at high temperatures (e.g., in deep-oil frying), inversions of the 
double bonds occur resulting in trans fatty acid isomers. Hydrogenated vegetable oils 
are currently a major source of trans fats in human diets. Despite trends towards 
reducing trans fats in margarines and hydrogenated vegetable oils in developed 
countries, the applicable technologies are not yet widely used in edible oils processing 
in Africa. Trans fats have been shown to be nearly as hypercholesterolemic as 
myristic or palmitic acids [20]. It was shown recently that palmitoleic acid, 16:1, 
alters serum lipoproteins in a manner similar to 14:0 and 12:0 [47]. However, trans 
FAs appeared less hypercholesterolemic than 14:0, the most hypercholesterolemic 
SAFA, and 12:0 [47].  It was also shown that Lpa was increased by a high trans fat 
diet compared to a stearic-enriched diet [47]. Since Lpa is a strong independent risk 
factor for CVD, a high trans fat diet may contribute to the risk of CVD [48]. Mensink 
and Katan concluded that since trans FAs raise LDL-cholesterol and decrease HDL-
cholesterol, they are as unfavourable as the SAFAs [49]. The AHA recommends 
lowering their dietary intake [12]. Due to the small amounts of unsaturated fatty acids 
in dairy fats, the dietary intake of trans fats in milk, butter and ghee is likely to be 
insignificant, while those with existing adverse cardiovascular risk factors are often 
advised to avoid margarine [5]. Milk from cattle, goats, sheep and camels also contain 
0.8-19% C4-C10 fatty acids, whose roles in CVD have not been reported much in the 
literature, despite indications that they may inhibit hepatic cholesterol synthesis 
and/or redistribute cholesterol from plasma to the liver.   
 
28% of bovine milk-fat comprises oleic, linoleic and linolenic acids. Oleic increases 
cholesterol esterification in hepatocytes, diminishes the free cholesterol pool, and 
enhances LDL-receptor activity [50]. However, epidemiological studies have not 
shown consistent effects of MUFAs on the risk for coronary arterial disease. 
Replacement of dietary SAFAs with oleic-rich diets has been shown to be as effective 
as substitution with PUFAs in lowering plasma LDL [51, 52]. It also has the 
advantage that it does not simultaneously lower HDL-cholesterol in 
hypercholesterolemic subjects [51, 52]. HDL has also been demonstrated to inhibit 
oxidative modification of LDL [53]. Because there may be an exchange of fatty acids 
and oxidized fatty acid products between LDL and HDL, HDL particles enriched 
with PUFAs may offer less protection to LDL. Thus, diets enriched with oleic rather 
than PUFAs might confer additional protection by generating both LDL particles that 
are more resistant to oxidation and HDL particles that inhibit oxidative modification, 
while optimizing both LDL and HDL-cholesterol levels [54]. Oleic acid is beneficial 
as regards atherosclerosis, as ecological studies have shown an inverse association 
between the intake of MUFAs and CVD mortality [55].  
 
Several epidemiological studies suggest that low tissue levels of LA might be an 
independent risk factor for CVD [56]. However, as a n-6 fatty acid, a dietary LA 
deficiency would be expected to lower both thromboxane A2 and prostaglandin I2 
concentrations due to the synthesis of less arachidonic acid [13]. Both thromboxane 
A2 and prostaglandin I2 particles are antiaggregatory and vasodilatory, pointing to the 
likely beneficial effects of consumption of adequate but low levels of LA. Conjugated 
linoleic acid (CLA), a fatty acid in milk and dairy products protects against 





animal models from which the metabolic effects of dietary fatty acids can be 
extrapolated to human beings. It can therefore be postulated that LA as found in milk-
fat may decrease the risk of CVD, despite the rarity of data on humans [22]. In a 
prospective and nested case-control study of 7450 Japanese participants aged 40-85 
years, and using frozen serum samples from cardiovascular risk surveys collected 
from three communities from 1984-1992, it was found that the nature of fatty acids in 
the diet influenced the occurrence of stroke [57]. The study showed that a high intake 
of LA may protect against ischaemic stroke, possibly through potential mechanisms 
of decreased blood pressure, reduced platelet aggregation, and enhanced 
deformability of erythrocytes. Furthermore, it has been shown that CLA fed to 
rodents can predispose to the formation of fatty streaks-the presumed precursors of 
atherosclerotic lesions in the aorta [18]. CLA may play a role in slowing the 
formation of atherosclerotic plaques in blood vessels. However, it is recognized that 
dietary LA favours oxidative modification of LDLs, increases platelet response to 
aggregation, and suppresses the immune system [55]. Also, a high LA intake reduces 
apolipoprotein A-1 production [6]. This lowers HDL thereby decreasing reverse 
cholesterol transport, and possibly increasing the risk of atherosclerosis. Biochemical 
evidence also suggests that increased levels of LA in vascular cells favours lipid 
peroxidation due to its unsaturation [13]. Increased n-6 PUFA dietary intake may 
reduce the cellular incorporation of n-3 PUFAs, thereby leading to unhealthy 
imbalances in tissue lipids, by influencing the activity of the delta desaturase enzyme 
through competitive inhibition. This results in greater formation of the aggregatory 
and inflammatory series 2 eicosanoids [13]. LA hydroperoxides have also been 
shown to have potential cytotoxic effects in vitro [58]. In 2000, the Board of the 
International Society for the Study of Fats and Lipids (ISSFAL) could not 
recommend an upper limit for LA intake beyond 2% of total energy due to 
controversy, inconsistency and lack of adequate data. Therefore, more research is 
necessary to resolve the controversies and establish a clear role for LA in CVDs.  
 
Alpha-linolenic acid (ALA) can be elongated to the long-chain EPA and DHA, but its 
other exact functions in the human body are not characterized in detail. Eicosanoids 
derived from EPA have different biological properties in contrast to those derived 
from arachidonic acid. Their effects result in decreased vasoconstriction, platelet 
aggregation and leukocyte toxicity. However, the exact mechanism of action of ALA 
in reducing coronary disease recurrence is unknown; nevertheless, the AHA Dietary 
Guidelines recommend increasing its intake, as for the long-chain n-3 fatty acids from 
fish [10]. ALA has been found in several studies to exert positive effects in reducing 
CVD mortality risk [59, 60]. Due to competition between LA and ALA for entry into 
the elongation and desaturation pathways for the synthesis of their respective 




Regarding CVDs, it seems beneficial to reduce the dietary intake of SAFAs and 
cholesterol, since it is well established on the basis of convincing evidence that 
reduction in serum total cholesterol results in reduction of coronary morbidity and 





of dietary cholesterol expands the small regulatory hepatic intracellular pool of free 
cholesterol, resulting in reduced LDL-receptor activity, reduced LDL-cholesterol 
catabolism, and increased serum total cholesterol and LDL-cholesterol.  The long-
chain SAFAs (C12: 0-C16: 0) interfere with the esterification process of free cholesterol, 
and by this mechanism enlarge the hepatic regulatory free cholesterol pool. Similar to 
the situation with dietary cholesterol excess, LDL-receptor transcription is reduced, 
resulting in diminished LDL catabolism. Oleic acid increases cholesterol 
esterification in hepatocytes, diminishes the free cholesterol pool and enhances LDL-
receptor activity. Trans fatty acids increase serum total cholesterol and LDL-
cholesterol levels, but their importance as independent risk factors for CVD has not 
consistently been verified. MUFAs have a neutral influence on cholesterol levels, 
while PUFAs tend to lower both total cholesterol and HDLs. It is advisable to reduce 
the consumption of full-fat milk, and rely more on skimmed milk in order to lower 
cholesterol and SAFAs intake. Further research into the relationship between milk 
intake and risk for CVD using case-control, clinical, and pathological approaches, 
rather than relying largely on epidemiological studies (which are often conflicting) 
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